Parameter
| Biomarker | poly(GP) | Full name | Polyglycylproline | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Disease Monitoring, Pathological Confirmation |
| Disease | Frontotemporal Dementia | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | CSF (ELISA, Targeted Mass Spectrometry) | ||
| Pathobiological Mechanisms | RAN translation product of C9orf72 repeat expansion, deposition causes oxidative stress and inflammation. | ||||
| Clinical Availability Status | Research validation stage | ||||
| Notes and Dynamics | CSF poly(GP) in symptomatic carriers is 2.8 times higher than in asymptomatic individuals, serving as an efficacy endpoint for antisense oligonucleotide therapy. | ||||